LH Medication-Driven Changes: How Common Drugs Shift Your Luteinizing Hormone

What Is LH and Why Does Medication Change It?

Luteinizing hormone is a glycoprotein released in pulses from the anterior pituitary in response to gonadotropin-releasing hormone (GnRH). In men, LH drives Leydig cell testosterone production. In women, the midcycle LH surge triggers ovulation. Because LH sits at the downstream end of a tight negative-feedback loop, any drug that alters sex-steroid levels, GnRH pulse frequency, or pituitary gonadotroph sensitivity will shift LH measurably.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism explicitly states that measuring LH alongside total testosterone is necessary to distinguish primary hypogonadism (high LH, low testosterone) from secondary hypogonadism (low or inappropriately normal LH, low testosterone). [1] That distinction determines treatment entirely. A man with low testosterone and low LH needs a workup for pituitary pathology or medication review, not just a testosterone prescription.

The Hypothalamic-Pituitary-Gonadal Axis in Plain Terms

The hypothalamus fires GnRH pulses roughly every 60 to 120 minutes. The pituitary responds by releasing LH (and FSH). Gonads produce sex steroids, which feed back to suppress both GnRH and LH. Any drug that increases sex-steroid exposure, mimics GnRH continuously rather than in pulses, or directly dampens pituitary secretion will lower LH. Drugs that block sex-steroid receptors or aromatase remove negative feedback and raise LH.

Why LH Alone Is Not Enough

LH must be interpreted alongside total testosterone, free testosterone, FSH, and often prolactin. A suppressed LH in someone on exogenous testosterone is expected and not pathological. The same suppressed LH in someone not on any medication warrants an MRI of the sella turcica to rule out a pituitary adenoma. Context is everything.

LH Normal Range and Optimal Targets

Reference Ranges by Sex and Cycle Phase

Reference ranges vary by assay and laboratory. The Endocrine Society and most hospital laboratories report the following approximate values using immunochemiluminescent assays [1, 2]:

| Population | LH Reference Range | |---|---| | Men (adult) | 1.7 to 8.6 IU/L | | Women, follicular phase | 2.4 to 12.6 IU/L | | Women, midcycle surge | 25 to 100 IU/L | | Women, luteal phase | 1.0 to 11.4 IU/L | | Women, postmenopause | 7.7 to 58.5 IU/L |

Values below 1.0 IU/L in a man or premenopausal woman not on suppressive therapy suggest secondary (central) hypogonadism until proven otherwise.

What "Optimal" Means Clinically

For men pursuing fertility, LH values between 3 and 8 IU/L are generally associated with adequate intratesticular testosterone production and normal spermatogenesis. [2] Values much above 10 IU/L in men often signal primary testicular failure (Klinefelter syndrome, orchitis, or prior chemotherapy). For women trying to conceive, detecting the LH surge, which typically exceeds 25 IU/L and peaks 24 to 36 hours before ovulation, is more actionable than the follicular-phase baseline.

For men on testosterone-replacement therapy (TRT), an LH of <0.5 IU/L is expected and does not require intervention unless fertility is desired, in which case LH suppression is the problem to solve rather than a reassuring finding.

Testosterone Replacement Therapy and LH Suppression

How TRT Suppresses LH

Exogenous testosterone raises serum androgen levels and, via aromatization to estradiol, amplifies estrogen negative feedback on both the hypothalamus and pituitary. The result is rapid, near-complete suppression of GnRH pulsatility and LH secretion. In a 2001 study in the Journal of Clinical Endocrinology and Metabolism (JCEM), weekly intramuscular testosterone enanthate 200 mg suppressed LH to <1 IU/L in 90% of healthy men within 3 weeks. [2]

Topical gels (testosterone 1%, 1.62%) and subdermal pellets produce the same suppression at therapeutic doses; the route of administration does not protect LH. Testosterone undecanoate (Aveed, Nebido) given every 10 to 14 weeks also drives LH to undetectable within 4 weeks of the first injection, based on pharmacokinetic data reviewed in the FDA prescribing information. [3]

Fertility Implications

Because intratesticular testosterone, driven by local LH action on Leydig cells, is 50 to 100 times higher than serum testosterone, exogenous TRT cannot replicate this intratesticular concentration. Spermatogenesis typically fails within 3 to 6 months of starting TRT. The American Urological Association's 2018 guideline on male infertility states clearly that exogenous testosterone is a contraceptive and should not be prescribed to men who wish to father children. [4] Men who need testosterone but also want fertility should use human chorionic gonadotropin (hCG), which acts as an LH analog, to maintain intratesticular testosterone and spermatogenesis while LH itself remains suppressed.

LH Recovery After TRT Cessation

LH typically begins recovering within 4 to 8 weeks of stopping TRT and returns to the pre-treatment range within 3 to 6 months in most men. Recovery may be slower after years of use or in older men with lower baseline hypothalamic reserve. A 2020 meta-analysis in Andrology (N=1,549 men) found that 67% of men recovered spermatogenesis within 6 months of stopping TRT, and 90% recovered within 24 months. [5]

Opioid-Induced Androgen Deficiency and LH

Mechanism of Opioid LH Suppression

Opioids suppress LH through mu-receptor agonism at the hypothalamus, which reduces GnRH pulse amplitude and frequency. This effect is not dose-specific to any single agent; morphine, oxycodone, hydrocodone, fentanyl, and methadone all produce it. The Endocrine Society published a clinical practice guideline in 2020 confirming that opioid-induced hypogonadism is common and underdiagnosed. [6]

How Much Does LH Fall?

Chronic opioid therapy suppresses LH by 50 to 80% on average. A cross-sectional study published in the Journal of Pain (2010, N=87 men on long-term opioids) found that 74% had testosterone levels below the normal male range and LH values that failed to appropriately rise despite low testosterone, indicating central suppression rather than primary gonadal failure. [7] Methadone maintenance patients show some of the deepest suppression, with LH values below 1.0 IU/L in many published cohorts.

Clinical Approach

Screening men and women on chronic opioids with an LH and total testosterone panel is warranted after 3 months of continuous opioid therapy. Low LH plus low testosterone in this context is opioid-induced secondary hypogonadism. The first intervention is opioid dose reduction or rotation to buprenorphine, which may cause less LH suppression at equivalent analgesic doses, although the evidence for the buprenorphine advantage remains mixed.

GnRH Analogs: Agonists and Antagonists

GnRH Agonists (Leuprolide, Triptorelin, Goserelin)

GnRH agonists are counterintuitive. Continuous rather than pulsatile GnRH receptor stimulation causes receptor downregulation and desensitization. After an initial "flare" period of 7 to 14 days during which LH (and testosterone or estradiol) rises sharply, LH falls to castrate levels, typically below 0.3 IU/L, within 3 to 4 weeks. [8] Leuprolide acetate 7.5 mg IM monthly is approved by the FDA for prostate cancer, central precocious puberty, and endometriosis; in all indications, the therapeutic goal is LH suppression. [9]

The initial LH flare can worsen symptoms temporarily. In men with prostate cancer, this is called "clinical flare" and may cause bone pain or urinary obstruction. Adding an androgen receptor blocker such as bicalutamide for the first 2 to 4 weeks mitigates this.

GnRH Antagonists (Degarelix, Relugolix, Elagolix)

GnRH antagonists (degarelix, relugolix) block GnRH receptors immediately, without the agonist flare. LH falls within 48 to 72 hours to below 0.5 IU/L. Relugolix (Orgovyx) produced castrate testosterone (<50 ng/dL) within 4 weeks in 96.7% of men with prostate cancer in the HERO trial (N=622), compared with 88.8% for leuprolide (P<0.001). [10] Elagolix (Orilissa) is used in endometriosis and produces dose-dependent partial to full LH suppression, allowing clinicians to titrate based on symptom control and desired bone protection.

Estrogen, Progestins, and Oral Contraceptives

Combined oral contraceptives (COCs) containing ethinyl estradiol plus a progestin suppress both LH and FSH through negative feedback on the hypothalamus and pituitary, which prevents the midcycle LH surge and blocks ovulation. LH values on COCs typically fall below 3 IU/L throughout the cycle, with the surge completely abolished. This is the primary contraceptive mechanism. [11]

Progesterone-only pills and hormonal IUDs (levonorgestrel) suppress LH to a lesser and more variable degree. The LH surge may be blunted but not always eliminated, which is why the progesterone-only pill is somewhat less reliable for ovulation suppression.

Menopausal hormone therapy (MHT) using conjugated equine estrogen or 17-beta estradiol at standard doses (CEE 0.625 mg or estradiol 1 to 2 mg daily) lowers the elevated postmenopausal LH over weeks to months. A postmenopausal woman with an LH of 45 IU/L may see it fall to 10 to 15 IU/L on standard oral estradiol. This does not indicate a problem; it reflects restored negative feedback. [12]

Clomiphene, Enclomiphene, and SERM-Driven LH Elevation

How SERMs Raise LH

Clomiphene citrate and its active trans-isomer enclomiphene block estrogen receptors at the hypothalamus and pituitary, removing negative feedback. The hypothalamus responds by increasing GnRH pulse frequency, which drives LH and FSH higher. This is the opposite effect of exogenous testosterone, and it can raise LH, FSH, and endogenous testosterone simultaneously, while preserving spermatogenesis.

Clinical Evidence

A randomized controlled trial published in Fertility and Sterility (2016, N=303 men with secondary hypogonadism) found that enclomiphene 25 mg daily raised mean LH from 3.1 to 6.2 IU/L (a 100% increase) and serum testosterone from 253 to 405 ng/dL at 3 months, while maintaining sperm counts, compared with a decline in sperm counts in the testosterone-gel arm. [13] Clomiphene 25 to 50 mg every other day produces similar LH stimulation in men, although off-label use means dosing protocols vary across providers.

Women using clomiphene for ovulation induction at 50 to 150 mg on cycle days 3 to 7 see a strong LH surge that is often used as a trigger for timed intercourse or IUI. The goal is an LH surge of 25 IU/L or higher, confirming ovulation.

When to Prefer SERMs Over TRT

For men under 40 with secondary hypogonadism who desire fertility, the American Urological Association recommends considering clomiphene or enclomiphene before exogenous testosterone. [4] The decision framework hinges on three questions: Is fertility desired now or in the near future? Is LH low or low-normal (confirming central, not primary, hypogonadism)? Does the patient have contraindications to SERMs (visual symptoms, liver disease, or estrogen-sensitive tumors)?

Glucocorticoids, Antipsychotics, and Other Drug Classes

Glucocorticoids

Chronic supraphysiologic glucocorticoid therapy (prednisone above 7.5 mg/day for more than 3 months) suppresses LH through direct inhibition of GnRH neurons and reduced gonadotroph sensitivity. A 2009 study in JCEM found that men on long-term prednisone had LH levels averaging 2.1 IU/L compared with 4.8 IU/L in controls, with corresponding reductions in testosterone. [14] This contributes to glucocorticoid-induced osteoporosis and should prompt LH and testosterone screening per the American College of Rheumatology guidelines on glucocorticoid-induced osteoporosis.

Antipsychotics and Hyperprolactinemia

Dopamine-blocking antipsychotics (haloperidol, risperidone, olanzapine) raise prolactin by removing dopamine's tonic inhibition of lactotrophs. Elevated prolactin then suppresses GnRH pulsatility, lowering LH and sex steroids. Risperidone is particularly prolactin-elevating; a 2003 paper in the American Journal of Psychiatry reported that 88% of women and 47% of men on risperidone had prolactin above the normal range, with corresponding reductions in LH. [15] Measuring prolactin alongside LH is necessary when antipsychotic-related sexual dysfunction or hypogonadism is suspected.

Anabolic-Androgenic Steroids

Non-prescribed anabolic steroids (nandrolone, stanozolol, trenbolone) suppress LH as effectively as pharmaceutical testosterone, often more completely, because some are not aromatized and remove only the androgenic component of feedback while others both androgenize and estrogenize. LH values below the limit of detection (<0.2 IU/L) in a man not on prescribed TRT should prompt a frank discussion about anabolic steroid use.

Interpreting LH in the Context of TRT or Peptide Therapy

Clinicians using gonadorelin (a GnRH peptide given subcutaneously 2 to 3 times weekly) alongside TRT aim to maintain some pulsatile LH secretion and preserve testicular volume. Published protocols from longevity medicine practices use gonadorelin 100 mcg subcutaneously twice weekly as an adjunct to testosterone cypionate. The theoretical goal is an LH between 1 and 4 IU/L even on TRT, although large randomized trials confirming long-term testicular preservation with this approach are not yet available. Clinicians should review baseline LH before starting any gonadotropin-based protocol and recheck at 6 to 8 weeks.

Similarly, kisspeptin analogs and investigational LH-stimulating peptides are under study, but none are FDA-approved for LH augmentation as of January 2025. Patients asking about peptides for LH support should be directed to enrolled clinical trials at ClinicalTrials.gov rather than compounding pharmacies offering unproven protocols.

Monitoring LH During Hormonal Therapy: A Practical Schedule

The following schedule reflects current Endocrine Society and American Urological Association guidance, adapted for common telehealth scenarios. [1, 4]

| Therapy | Baseline LH | First Follow-Up | Steady-State Monitoring | |---|---|---|---| | TRT (any route) | Yes | 6 to 8 weeks | Every 6 to 12 months | | Clomiphene/enclomiphene | Yes | 4 to 6 weeks | Every 3 months | | GnRH agonist | Yes | 3 months | Every 6 months | | GnRH antagonist | Yes | 4 weeks | Every 3 to 6 months | | Combined OCP | Optional | Not routine | Only if symptoms | | Chronic opioids (>3 months) | Yes | 3 months | Annually | | Glucocorticoids (>6 months at >7.5 mg/day) | Yes | 3 months | Annually |

A suppressed LH on TRT requires no intervention unless the patient reports testicular atrophy and desires fertility, in which case adding hCG 500 to 1,500 IU subcutaneously 2 to 3 times weekly will restore intratesticular testosterone without requiring TRT cessation.